sponsored
PatientsVille.com Logo

PatientsVille

Citalopram Medical Research Studies

Up-to-date List of Citalopram Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Citalopram Medical Research Studies

Rank Status Study
1 Recruiting Escitalopram PIndolol ONset of Action
Condition: Unipolar Depression
Interventions: Drug: Escitalopram, pindolol;   Drug: Escitalopram
Outcome Measures: MADRS score change between baseline and 2 weeks of treatment;   Response/remission (MADRS) at 6 weeks;   Adverse events;   Correlation of drug level of pindolol and/or Escitalopram and clinical outcome (primary outcome) between treatment groups
2 Recruiting Lexapro®'s Efficacy After Dose Escalation in Remission Study
Condition: Major Depressive Disorder
Intervention: Drug: Escitalopram
Outcome Measures: Montgomery-Åsberg Depression Rating Scale (MADRS);   Hamilton Depression Rating Scale-17 items (HAM-D);   Hamilton Anxiety Rating Scale (HAM-A);   Clinical Global Impression-severity (CGI-S);   Clinical Global Impression-Improvement (CGI-I);   Beck's Depression Inventory(BDI);   WHO Quality Of Life scale Abbreviated Version(WHOQOL-BREF);   Clinically Useful Depression Outcome Scale (CUDOS);   Short From-36 Health survey (SF-36 Health survey)
3 Unknown  Circadian Effects of Escitalopram
Condition: Depression
Intervention: Drug: placebo/Escitalopram
Outcome Measures: Resetting effect of Escitalopram on the circadian pacemaker;   Correlation between improvement in depression with Escitalopram and the degree of realignment between the timing of sleep and the timing of the biological clock.
4 Recruiting Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder
Conditions: Irritable Bowel Syndrome;   Panic Disorder
Intervention: Drug: Escitalopram
Outcome Measures: Gastrointestinal Symptom Rating Scale (GSRS).;   State Trait Anxiety Inventory (STAI).
5 Recruiting Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial
Conditions: Major Depressive Disorder;   Major Depressive Disorder, Recurrent, Unspecified;   Major Depressive Disorder, Single Episode, Unspecified
Interventions: Drug: Escitalopram oxalate;   Device: transcranial direct current stimulation
Outcome Measures: Change in Hamilton Rating Scale for Depression, 17 items (HAMD17);   Change in Montgomery-Asberg Depression Rating Scale (MADRS);   Change in Beck Depression Inventory (BDI);   Hamilton Rating Scale for Depression, 17 items (HAMD17)
6 Not yet recruiting Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)
Condition: Major Depressive Disorder (MDD)
Interventions: Drug: Agomelatine;   Drug: Escitalopram
Outcome Measures: Change from baseline in markers of sympathetic nervous system activity.;   Change from baseline in the magnitude of morning surge in blood pressure.;   To determine the association between sympathetic nervous system activity and left ventricular hypertrophy.;   Change from baseline in insulin resistance.;   Change from baseline on markers of cardiac risk.
7 Unknown  The Effects of Escitalopram on Cytokines
Condition: Depression
Intervention: Drug: Escitalopram
Outcome Measures: The changes in cytokines;   The changes in Hamilton Depression Rating Scale
8 Unknown  Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning
Conditions: Depression;   Continuous Antidepressant Abuse;   Adverse Reaction to Drug
Intervention: Drug: Escitalopram
Outcome Measures: antidepressant response at 2,4,6,8 weeks A/E monitoring at 1,2,4,6,8 weeks;   biological value at 0 week and 8 weeks
9 Unknown  Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)
Condition: Major Depression
Interventions: Drug: Escitalopram;   Drug: nortriptyline
Outcome Measures: Hamilton depression rating scale;   Drop out due to side-effects of drugs
10 Unknown  Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain
Conditions: Low Back Pain;   Depression
Interventions: Drug: Escitalopram;   Drug: Placebo
Outcome Measures: In comparison to placebo-treated patients, patients with treated with Cipralex report a significant reduction in depressive symptoms (>= 50% HAMD score) after 4 weeks of treatment.;   In comparison to placebo, subjects treated with Cipralex report a significant reduction in pain intensity (>= 50% reduction of pain questionnaire score or VAS) after 12 weeks of treatment.;   In comparison with placebo, subjects treated with Cipralex report a significant improvement in physical and everyday functioning after 12 weeks of treatment.;   Personality traits do not have a significant influence on outcome regarding depressive traits, pain intensity and functioning.;   Personality disorders are significantly influencing worse outcome regarding depressive traits, pain intensity and functioning.
11 Recruiting A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom
Condition: Depressive Disorder, Major
Intervention: Drug: Escitalopram
Outcome Measures: Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire, Short Form (Q-LES-Q-SF);   Change From Baseline in Sheehan Disability Scale (SDS);   Remission Rate at Week 8;   Onset of Effect Rate at Week 1;   Onset of Effect Rate at Week 2;   Change From Baseline to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Scores;   Change From Baseline to Week 8 in Hamilton Anxiety Scale (HAMA) Scores;   Change From Baseline to Week 8 in Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) Scores
12 Unknown  Cognitive Behavioural Analysis System of Psychotherapy (CBASp) Versus Escitalopram in Chronic Depression
Condition: Chronic Depression
Interventions: Other: CBASP psychotherapy;   Drug: Escitalopram
Outcome Measures: Depressive symptomatology after 8 weeks after randomization as measured by the MADRS;   Depressive symptoms and remission 28 weeks after randomization; social, interpersonal and work function 28 weeks after randomization
13 Recruiting Brain Aging and Treatment Response in Geriatric Depression
Conditions: Mild Neurocognitive Disorder;   MCI;   Depression
Interventions: Drug: Escitalopram;   Drug: Memantine;   Drug: Placebo
Outcome Measures: Change in Hamilton Depression Rating Scale (HDRS) scores;   Change in cognitive domain scores
14 Not yet recruiting The ISLAND Study: InSuLa Assessed Needs for Depression
Condition: Depression
Interventions: Drug: Escitalopram;   Behavioral: Cognitive Behavioral Therapy;   Other: Combination treatment (Escitalopram + CBT)
Outcome Measures: Remission from major depressive episode;   Response to treatment
15 Unknown  Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy
Condition: Marijuana Dependence
Intervention: Drug: Escitalopram
Outcome Measures: Clean urine THC samples;   Questionnaire ratings of anxiety and depression and withdrawal symptoms
16 Unknown  Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder in Veterans of Operation Enduring Freedom and Iraqi Freedom
Conditions: Autonomic Reactivity;   Cardiac Functioning
Intervention: Drug: Escitalopram
Outcome Measures: 1. To investigate the effects of Escitalopram on cardiac vagal function as measured by R-R interval variability, especially in the HF (0.15-0.5 Hz) band in OEF/OIF veterans with PTSD;   2. To investigate the effects of Escitalopram on an absolute or relative decrease in cardiac sympathetic function and serious cardiac side effects as measured by QT interval variability in OEF/OIF veterans with PTSD.;   1. To determine the effectiveness of Escitalopram in OEF/OIF veterans with PTSD
17 Recruiting Investigation of Tibolone and Escitalopram in Perimenopausal Depression
Condition: Perimenopausal Depression
Interventions: Drug: Tibolone;   Drug: Escitalopram;   Drug: Natvia
Outcome Measures: Montgomery and Asberg Depression Rating Scale;   Short Form-36 Health Survey (SF-36);   Pittsburgh Sleep Quality Index;   Adverse Symptoms Checklist;   Beck Depression Inventory Scale
18 Unknown  Pharmacokinetic and Pharmacodynamic Effects of Escitalopram Depending on Genetic Polymorphisms of the ABCB1-gene
Condition: Pharmacokinetics
Intervention: Drug: Escitalopram
Outcome Measures: Brain levels of Escitalopram as assessed by a 19-F magnetic resonance spectroscopy;   Sleep-EEG, functional MRI, learning, gene expression, metabolic changes
19 Recruiting DECIFER: DEpression and Citalopram In First Episode Recovery
Conditions: Schizophrenia;   Schizophreniform Disorder
Interventions: Drug: Citalopram;   Behavioral: Psychoeducation;   Behavioral: Cognitive Behavioral Therapy (CBT);   Radiation: Functional Magnetic Resonance Imaging (fMRI);   Drug: Placebo
Outcome Measures: Calgary Depression Scale for Schizophrenia (CDSS);   Scale for the Assessment of Negative Symptoms (SANS);   Brief Psychiatric Rating Scale (BPRS);   InterSePT Scale for Suicidal Thinking (ISST);   Heinrich Quality of Life Scale (QOL)
20 Unknown  Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
Conditions: Major Depression;   Pain;   Abdominal Pain
Interventions: Drug: Escitalopram;   Drug: Reboxetine;   Other: No intervention
Outcome Measure: rectal distension Transcutaneous Electrical Neuro-Stimulation

These studies may lead to new treatments and are adding insight into Citalopram etiology and treatment.

A major focus of Citalopram research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Citalopram